LB Pharmaceuticals Inc.

09/16/2025 | Press release | Distributed by Public on 09/16/2025 13:46

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Vida Ventures GP III, L.L.C.
2. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [LBRX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
10100 SANTA MONICA BOULEVARD, SUITE 1500
3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025
(Street)
LOS ANGELES, CA 90067
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/12/2025 C(1) 547,648 A (1) 547,648 I By Vida Ventures III, L.P.(2)(3)
Common Stock 09/12/2025 C(1) 1,262 A (1) 1,262 I By Vida Ventures III-A, L.P.(4)
Common Stock 09/12/2025 P 332,566 A $15 880,214 I By Vida Ventures III, L.P.(2)(3)
Common Stock 09/12/2025 P 767 A $15 2,029 I By Vida Ventures III-A, L.P.(4)
Common Stock 1,434 I By Vida Ventures Management Co. LLC(5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Preferred Stock (1) 09/12/2025 C 13,302,666 (1) (1) Common Stock 547,648 $ 0 0 I By Vida Ventures III, L.P.(2)(3)
Series C Preferred Stock (1) 09/12/2025 C 30,667 (1) (1) Common Stock 1,262 $ 0 0 I By Vida Ventures III-A, L.P.(4)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Vida Ventures GP III, L.L.C.
10100 SANTA MONICA BOULEVARD
SUITE 1500
LOS ANGELES, CA 90067
X
Vida Ventures III, L.P.
10100 SANTA MONICA BOULEVARD
SUITE 1500
LOS ANGELES, CA 90067
X
Vida Ventures III-A, L.P.
10100 SANTA MONICA BOULEVARD
SUITE 1500
LOS ANGELES, CA 90067
X
Belldegrun Arie
10100 SANTA MONICA BOULEVARD
SUITE 1500
LOS ANGELES, CA 90067
X
Vida Ventures Management Co. LLC
10100 SANTA MONICA BOULEVARD
SUITE 1500
LOS ANGELES, CA 90067
X

Signatures

VIDA VENTURES GP III, L.L.C., By: /s/ Jean-Philippe Kouakou-Zebouah, its Managing Member 09/16/2025
**Signature of Reporting Person Date
VIDA VENTURES III, L.P., By: Vida Ventures GP III, L.L.C., its general partner, By: /s/ Jean-Philippe Kouakou-Zebouah, its Managing Member 09/16/2025
**Signature of Reporting Person Date
VIDA VENTURES III-A, L.P., By: Vida Ventures GP III, L.L.C., its general partner, By: /s/ Jean-Philippe Kouakou-Zebouah, its Managing Member 09/16/2025
**Signature of Reporting Person Date
VIDA VENTURES MANAGEMENT CO., LLC, By: /s/ Jean-Philippe Kouakou-Zebouah, its Managing Member 09/16/2025
**Signature of Reporting Person Date
ARIE BELLDEGRUN By: /s/ Jean-Philippe Kouakou-Zebouah, his attorney-in-fact 09/16/2025
**Signature of Reporting Person Date
HELEN KIM By: /s/ Jean-Philippe Kouakou-Zebouah, her attorney-in-fact 09/16/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.
(2) These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee").
(3) (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
(4) These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
(5) These shares are held directly by Vida Ventures Management Co., LLC ("Vida Management"). Each Investment Committee Member (as defined below) disclaims beneficial ownership of the securities held of record by Vida Management, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
LB Pharmaceuticals Inc. published this content on September 16, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 16, 2025 at 19:47 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]